These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 21710803)
81. Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP. Armstrong J N Engl J Med; 2011 May; 364(18):1689-91. PubMed ID: 21410391 [No Abstract] [Full Text] [Related]
82. Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth. Calda P J Matern Fetal Neonatal Med; 2009 Jun; 22(6):540-2. PubMed ID: 19089768 [No Abstract] [Full Text] [Related]
83. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. O'Brien JM Obstet Gynecol; 2012 Feb; 119(2 Pt 1):384-5; author reply 385-6. PubMed ID: 22270303 [No Abstract] [Full Text] [Related]
85. What is in a name? A higher cost! Hansen KA S D Med; 2011 Jun; 64(6):194-5. PubMed ID: 21710803 [No Abstract] [Full Text] [Related]
86. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Bailit JL; Votruba ME Am J Obstet Gynecol; 2007 Mar; 196(3):219.e1-7. PubMed ID: 17346527 [TBL] [Abstract][Full Text] [Related]
87. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery. Facchinetti F; Vaccaro V Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671 [TBL] [Abstract][Full Text] [Related]
88. Orphan drugs: the question of products liability. Scharf SF Am J Law Med; 1985; 10(4):491-513. PubMed ID: 3911776 [TBL] [Abstract][Full Text] [Related]
89. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins. Christian MS; Brent RL; Calda P J Matern Fetal Neonatal Med; 2007 Feb; 20(2):89-112. PubMed ID: 17437208 [TBL] [Abstract][Full Text] [Related]